Arbutus Biopharma (ABUS) Equity Ratio: 2009-2025
Historic Equity Ratio for Arbutus Biopharma (ABUS) over the last 14 years, with Sep 2025 value amounting to 0.79.
- Arbutus Biopharma's Equity Ratio rose 4.08% to 0.79 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79, marking a year-over-year increase of 4.08%. This contributed to the annual value of 0.74 for FY2024, which is 0.69% up from last year.
- Arbutus Biopharma's Equity Ratio amounted to 0.79 in Q3 2025, which was down 1.42% from 0.80 recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's Equity Ratio ranged from a high of 0.83 in Q4 2021 and a low of 0.68 during Q1 2025.
- Over the past 3 years, Arbutus Biopharma's median Equity Ratio value was 0.76 (recorded in 2024), while the average stood at 0.75.
- In the last 5 years, Arbutus Biopharma's Equity Ratio grew by 11.40% in 2021 and then fell by 15.49% in 2022.
- Quarterly analysis of 5 years shows Arbutus Biopharma's Equity Ratio stood at 0.83 in 2021, then declined by 15.49% to 0.70 in 2022, then increased by 4.84% to 0.73 in 2023, then increased by 0.69% to 0.74 in 2024, then rose by 4.08% to 0.79 in 2025.
- Its Equity Ratio stands at 0.79 for Q3 2025, versus 0.80 for Q2 2025 and 0.68 for Q1 2025.